CardioBrief: Enormous NOAC Study Halted for 'Overwhelming Efficacy'

(MedPage Today) -- Rivaroxaban cut CV events in coronary and peripheral disease patients
via CardioBrief: Enormous NOAC Study Halted for 'Overwhelming Efficacy'
by